Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.33 |
| ▸ | CDC25B | P30305 | 6/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17106669 | 0.93 | PTPN1 (0.34) | PDE2APTPN1CDC25BHTR1AHSPA5 | |
| SCHEMBL19412708 | 0.93 | PTPN1 (0.34) | PDE2APTPN1CDC25BHTR1AHSPA5 | |
| SCHEMBL18788247 | 0.87 | PDE2A (0.35) | PDE2APTPN1CDC25BHTR1AHSPA5 | |
| SCHEMBL22579701 | 0.83 | HRH4 (0.31) | — | |
| SCHEMBL22569896 | 0.83 | TNK2 (0.31) | — | |
| SCHEMBL17131351 | 0.81 | TSHR (0.31) | — | |
| SCHEMBL19758149 | 0.81 | TSHR (0.31) | — | |
| SCHEMBL24160877 | 0.81 | PDE2A (0.34) | PDE2APTPN1CDC25BHTR1ABCHE | |
| SCHEMBL18788242 | 0.81 | PDE2A (0.34) | PDE2APTPN1CDC25BHTR1ABCHE | |
| SCHEMBL17106824 | 0.80 | PTPN1 (0.36) | PDE2APTPN1CDC25BHTR1AHSPA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3956341-A1 | CD73 INHIBITORS | Bioardis LLC (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | PDE2A 431/4885PTPN1 922/4885CDC25B 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.